Ascendis Pharma A/S
- Market cap
- 15.03B
- P/E (TTM)i
- 18.23
- P/Bi
- 9.35
- EPSi
- -4.21
- Div yieldi
- 0.00%
- 52W posi
- 44%
Anonymous reader poll. Unscientific, not investment advice.
Ascendis Pharma A/S shares were changing hands at 228.41, up 1.04% on the day. The company carries a market value of roughly 15.03B, the #1127 most valuable US-listed company we track. Wall Street's 18-analyst consensus lands on Buy, with a price target averaging 317.47 (+39% from here). Over the past year the stock has ranged from 186.05 to 282.15; it now sits 44% up that band.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 2 weeks.
- Its last 6 Sell calls were actually followed by a +4% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -2.8% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 6.0% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation D+
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 18.2x | Better than 53% |
| Forward P/E | 32.3x | Better than 17% |
| Price / Sales | 12.7x | Better than 10% |
| P/E vs own 5-yr range | 92nd pctl | Better than 11% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 86.8% | Better than 96% |
| Operating margin | -18.9% | Better than 5% |
| Net margin | -31.7% | Better than 4% |
| Return on equity | -818.4% | Better than 0% |
| Return on invested capital | -71.6% | Better than 1% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -14.6% | Better than 18% |
| 6-month return | 3.4% | Better than 45% |
| 12-month return (ex latest month) | 28.3% | Better than 64% |
| Distance below 52-week high | 19.2% | Better than 49% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.0x | Better than 27% |
| Debt to assets | 66.9% | Better than 18% |
| Interest coverage | -1.6x | Better than 9% |
| Free cash flow / net income | 125.4% | Better than 60% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 39.2% | Better than 73% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 226.05
- Open
- 224.36
- Day range
- 223.05 - 229.00
- Avg price
- 227.05
- Volume
- 820.55K
- Turnover
- 186.30M
- Turnover ratei
- 1.25%
- Volume ratioi
- 0.97
- Amplitudei
- 2.63%
- 52-week rangei
- 186.05 - 282.15
Valuation
- P/Ei
- -54.27
- P/E (TTM)i
- 18.23
- P/Bi
- 9.35
- EPSi
- -4.21
- Book value / shi
- 24.44
- Net profit
- -276.97M
- Net assets
- 1.61B
Share structure
- Market cap
- 15.03B
- Float capi
- 15.02B
- Shares out
- 65.80M
- Float sharesi
- 65.77M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-01-28
19.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-22.87M net over the window
Short interest
- Shares short
- 3.96M
- % of floati
- 6.02%
- Days to coveri
- 4.90
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Ascendis Pharma A/S (ASND)?
Ascendis Pharma A/S last traded at 228.41. The quote on this page refreshes every few seconds while US markets are open.
What is Ascendis Pharma A/S's market cap?
About 15.03B.
What is the P/E ratio of Ascendis Pharma A/S?
The trailing twelve-month P/E is 18.23. The Valuation tab shows it against the stock's own five-year range.
Does Ascendis Pharma A/S pay a dividend?
Ascendis Pharma A/S does not currently pay a regular dividend.
Is Ascendis Pharma A/S a buy according to analysts?
The consensus of 18 analysts is a Buy rating, with an average 12-month price target of 317.47, which implies 39.0% upside from the current price. This is not investment advice.
What is Ascendis Pharma A/S's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Ascendis Pharma A/S a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-10-07 23:39:45 · For reference only, not investment advice and not tailored to your situation.